MAP2K7 and non-small cell lung carcinoma: Similarly, in the present study, the PFS for first- and second-line BRAF/MEK-targeted therapy was also longer than that for chemotherapy with or without bevacizumab (first-line: NA vs. 4.0 months, P = 0.025; second-line: 6.0 vs. 4.6 months, P = 0.017), indicating that BRAF/MEK-targeted therapy is a viable choice for advanced NSCLC patients with the BRAF-V600E mutation.